

Adult CIRB - Early Phase Emphasis Meeting Agenda

August 3, 2021

I Continuing Review

10126, A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma (Protocol Version Date 05/14/21)

II Continuing Review

10170, A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (Protocol Version Date 08/24/20)

III Continuing Review

10184, Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (Protocol Version Date 04/15/21)

IV Continuing Review

10276, A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Protocol Version Date 05/12/21)

V New Study - Initial Review

10466, A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer (Protocol Version Date 06/16/21)
